{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:54:36Z","timestamp":1785704076505,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.05.007","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:21:28Z","timestamp":1779466888000},"page":"479-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Progress in Clonal Hematopoiesis of Indeterminate Potential\/Clonal Cytopenia of Uncertain Significance"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1904-1024","authenticated-orcid":false,"given":"Jayanshu","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-4962","authenticated-orcid":false,"given":"Uma","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.clml.2026.05.007_bib0001","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.05.007_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.05.007_bib0003","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood.V83.4.931.931","article-title":"Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27\u03b2 DNA probe","volume":"83","author":"Fey","year":"1994","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.05.007_bib0004","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat Genet"},{"issue":"26","key":"10.1016\/j.clml.2026.05.007_bib0005","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.05.007_bib0006","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.exphem.2020.01.008","article-title":"60 Years of clonal hematopoiesis research: From X-chromosome inactivation studies to the identification of driver mutations","volume":"83","author":"Ayachi","year":"2020","journal-title":"Exp Hematol"},{"issue":"7","key":"10.1016\/j.clml.2026.05.007_bib0007","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2026.05.007_bib0008","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.05.007_bib0009","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jacc.2019.06.007","article-title":"Clonal hematopoiesis at crossroads of aging, cardiovascular diseases, and cancer: JACC topic of the week","volume":"74","author":"Libby","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.clml.2026.05.007_bib0010","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and impacts clinical outcome","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.clml.2026.05.007_bib0011","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.70205","article-title":"Clonal hematopoiesis of indeterminate potential and Clonal cytopenias of undetermined significance: 2026 update on clinical associations and management recommendations","volume":"101","author":"Mangaonkar","year":"2026","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.007_bib0012","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1182\/blood-2023-186721","article-title":"1-Year data analysis from a cancer center molecular tumor board dedicated to clonal hematopoiesis","volume":"142","author":"Micol","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.007_bib0013","article-title":"Real world experience of patient outcomes in a dedicated clonal hematopoiesis hematology clinic","volume":"146","author":"Jain","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.05.007_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.clml.2026.05.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0318300","article-title":"Error-corrected ultradeep next-generation sequencing for detection of clonal haematopoiesis and haematological neoplasms \u2013 sensitivity, specificity and accuracy","volume":"20","author":"Tursky","year":"2025","journal-title":"PLOS One"},{"issue":"1","key":"10.1016\/j.clml.2026.05.007_bib0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/joim.70037","article-title":"The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all-cause mortality","volume":"299","author":"Larsen","year":"2026","journal-title":"J Intern Med"},{"issue":"20","key":"10.1016\/j.clml.2026.05.007_bib0017","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2024024187","article-title":"JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism","volume":"144","author":"Zon","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2026.05.007_bib0018","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2025.07.058","article-title":"Clonal hematopoiesis and cardiovascular outcomes in older women","volume":"86","author":"Ezzat","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.clml.2026.05.007_bib0019","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/eurheartj\/ehaa845","article-title":"Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations","volume":"42","author":"Assmus","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.clml.2026.05.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"issue":"9","key":"10.1016\/j.clml.2026.05.007_bib0021","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41588-023-01472-1","article-title":"Multiparameter prediction of myeloid neoplasia risk","volume":"55","author":"Gu","year":"2023","journal-title":"Nat Genet"},{"issue":"19","key":"10.1016\/j.clml.2026.05.007_bib0022","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2024024756","article-title":"Risk prediction for clonal cytopenia: multicenter real-world evidence","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2026.05.007_bib0023","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.05.007_bib0024","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.2021011323","article-title":"Relationship between clone metrics and clinical outcome in clonal cytopenia","volume":"138","author":"Gall\u00ec","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.007_bib0025","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025018770","article-title":"A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study","author":"DeZern","year":"2026","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2026.05.007_bib0026","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1111\/bjh.19423","article-title":"Natural history of clonal haematopoiesis seen in real-world haematology settings","volume":"204","author":"Patel","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.05.007_bib0027","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bjh.19905","article-title":"Predicting therapy-related myeloid neoplasms after CAR-T with the clonal haematopoiesis risk score (CHRS)","volume":"206","author":"Galli","year":"2025","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2026.05.007_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.102290","article-title":"Clonal hematopoiesis risk score (CHRS) evaluation as a prognostic marker for death in cardio-oncology cohort","volume":"4","author":"Singh","year":"2025","journal-title":"JACC Adv"},{"issue":"5","key":"10.1016\/j.clml.2026.05.007_bib0029","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41375-025-02564-z","article-title":"Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms","volume":"39","author":"Chien","year":"2025","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2026.05.007_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(25)00137-1","article-title":"Clonal haematopoiesis to clonal cytopenias: unravelling disease evolution over time","volume":"12","author":"Kirschner","year":"2025","journal-title":"Lancet Haematol"},{"issue":"19","key":"10.1016\/j.clml.2026.05.007_bib0031","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180069","article-title":"Distinct landscape and clinical implications of therapy-related clonal hematopoiesis","volume":"134","author":"Takahashi","year":"2024","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.clml.2026.05.007_bib0032","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.clml.2026.05.007_bib0033","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1038\/s41375-020-0896-8","article-title":"Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking","volume":"34","author":"Dawoud","year":"2020","journal-title":"Leukemia"},{"issue":"7831","key":"10.1016\/j.clml.2026.05.007_bib0034","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clml.2026.05.007_bib0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.clml.2026.05.007_bib0036","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2026.05.007_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246385","article-title":"PARP inhibitors and myeloid neoplasms: a double-edged sword","volume":"13","author":"Csizmar","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.clml.2026.05.007_bib0038","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211872","article-title":"Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis","volume":"218","author":"Kim","year":"2021","journal-title":"J Exp Med"},{"issue":"14","key":"10.1016\/j.clml.2026.05.007_bib0039","first-page":"1606","article-title":"Clonal hematopoiesis and nonhematologic disorders","volume":"136","author":"Jaiswal","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2026.05.007_bib0040","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa2413361","article-title":"Tumor-infiltrating clonal hematopoiesis","volume":"392","author":"Pich","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2026.05.007_bib0041","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-023-02397-2","article-title":"Clonal hematopoiesis is associated with protection from Alzheimer\u2019s disease","volume":"29","author":"Bouzid","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.05.007_bib0042","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Version 1.2026. 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf Accessed: March 15, 2026."},{"key":"10.1016\/j.clml.2026.05.007_bib0043","unstructured":"Borate U. A randomized double-blind placebo-controlled phase II multi-center study of inflammation modification of canakinumab to prevent leukemic progression of clonal cytopenias of unknown significance (CCUS): IMPACT study. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT05641831. Accessed: March 12, 2026."},{"key":"10.1016\/j.clml.2026.05.007_bib0044","unstructured":"M.D. Anderson Cancer Center. A phase 2 study evaluating olutasidenib in patients with IDH1-mutated clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndromes\/chronic myelomonocytic leukemia. clinicaltrials.gov; 2026. https:\/\/clinicaltrials.gov\/study\/NCT06566742 Accessed: March 12, 2026."},{"key":"10.1016\/j.clml.2026.05.007_bib0045","unstructured":"Washington University School of Medicine. A pilot study of enasidenib for patients with clonal cytopenia of undetermined significance and mutations in IDH2: a decentralized trial. clinicaltrials.gov; 2026. https:\/\/clinicaltrials.gov\/study\/NCT06240754 Accessed: March 12, 2026."},{"key":"10.1016\/j.clml.2026.05.007_bib0046","unstructured":"Gr\u00f8nb\u00e6k K. STOP-LEUKEMIA: repurposing Metformin As a leukemia-preventive drug in CCUS and LR-MDS. clinicaltrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT04741945 Accessed: March 12, 2026."},{"key":"10.1016\/j.clml.2026.05.007_bib0047","unstructured":"Institute of Hematology & Blood Diseases Hospital, China. Metformin inhibits DNMT3A clonal hematopoiesis in acute leukemia: a single-arm clinical study. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT07188740 Accessed: March 12, 2026."},{"key":"10.1016\/j.clml.2026.05.007_bib0048","unstructured":"Washington University School of Medicine. Pilot study of statins in patients with clonal cytopenia of undetermined significance (CCUS) and myelodysplastic syndromes (MDS). clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT05483010 Accessed: March 12, 2026."},{"key":"10.1016\/j.clml.2026.05.007_bib0049","unstructured":"Mikkelsen S.U., Vallentin A., Nielsen A., et al. Vitamin C supplementation in patients with clonal cytopenia of undetermined significance or low-risk myeloid malignancies: results from EVI-2, a randomized, placebo-controlled phase 2 study. 2024. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/4136519\/stine.ulrik.mikkelsen.vitamin.c.supplementation.in.patients.with.clonal.html Accessed: March 10, 2026."},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.007_bib0050","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1182\/blood-2024-201437","article-title":"Oral vitamin C supplementation modulates inflammatory cytokines in clonal cytopenia of undetermined significance and low-risk myeloid malignancies: results from EVI-2 trial","volume":"144","author":"Al-Mousawi","year":"2024","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2026.05.007_bib0051","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood.2024024962","article-title":"High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.007_bib0052","unstructured":"Mayo Clinic. Phase 2 trial of high dose intravenous ascorbic acid as an adjunct to salvage chemotherapy in relapsed or refractory lymphoma, patients with clonal cytopenia of undetermined significance, and chronic myelomonocytic leukemia. clinicaltrials.gov; 2026. https:\/\/clinicaltrials.gov\/study\/NCT03418038 Accessed: March 12, 2026."},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.007_bib0053","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-635","article-title":"Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: a phase II decentralized clinical trial","volume":"146","author":"Bolton","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.007_bib0054","first-page":"1","article-title":"CDK4\/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis","author":"Chan","year":"2026","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2026.05.007_bib0055","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2024-203837","article-title":"High-risk ccus is clinically indistinguishable from low-risk myelodysplastic syndromes\/neoplasms","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.007_bib0056","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1182\/blood-2022-169710","article-title":"CCUS and low-risk MDS are inherently similar, sharing clonal and clinical features","volume":"140","author":"Ferrone","year":"2022","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:19:35Z","timestamp":1785701975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2152265026001503"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Progress in Clonal Hematopoiesis of Indeterminate Potential\/Clonal Cytopenia of Uncertain Significance","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}